about
Genomics of adaptation during experimental evolution of the opportunistic pathogen Pseudomonas aeruginosaMultidrug resistance in bacteriaCandida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agentsDesign of O -Acetylserine Sulfhydrylase Inhibitors by Mimicking NatureIn Vivo, In Vitro, and In Silico Characterization of Peptoids as Antimicrobial AgentsStructural and Functional Characterization of the LPS Transporter LptDE from Gram-Negative Pathogens.Isolation and identification of a Paenibacillus polymyxa strain that coproduces a novel lantibiotic and polymyxin.Comprehensive identification of essential Staphylococcus aureus genes using Transposon-Mediated Differential Hybridisation (TMDH)Nationwide Surveillance of Clinical Carbapenem-resistant Enterobacteriaceae (CRE) Strains in China.High yield expression of an AHL-lactonase from Bacillus sp. B546 in Pichia pastoris and its application to reduce Aeromonas hydrophila mortality in aquaculture.Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model.In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class.Multi-drug resistant gram negative infections and use of intravenous polymyxin B in critically ill children of developing country: retrospective cohort study.Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.Sequential mechanism of assembly of multidrug efflux pump AcrAB-TolC.Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.Diffusible signal factor (DSF) quorum sensing signal and structurally related molecules enhance the antimicrobial efficacy of antibiotics against some bacterial pathogensClinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula.Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model.In vitro antimicrobial studies of silver carbene complexes: activity of free and nanoparticle carbene formulations against clinical isolates of pathogenic bacteria.Increased prevalence of carbapenem resistant Enterobacteriaceae in hospital setting due to cross-species transmission of the bla NDM-1 element and clonal spread of progenitor resistant strains.Staphylococcus aureus Infection Induced Oxidative Imbalance in Neutrophils: Possible Protective Role of Nanoconjugated VancomycinAn emptying quiver: antimicrobial drugs and resistance.High performance liquid chromatography-mass spectrometry assay for polymyxin B1 and B2 in human plasma.Application of 3D NMR for Structure Determination of Peptide Natural Products.Pharmacodynamics of antimicrobials: treatment optimisation.Permeability Barrier of Gram-Negative Cell Envelopes and Approaches To Bypass It.Nitric oxide mediated Staphylococcus aureus pathogenesis and protective role of nanoconjugated vancomycinBiochemical characters and antibiotic susceptibility of Staphylococcus aureus isolates.Quorum-quenching microbial infections: mechanisms and implicationsBranched Peptide, B2088, Disrupts the Supramolecular Organization of Lipopolysaccharides and Sensitizes the Gram-negative Bacteria.Identification of Candida species in patients with oral lesion undergoing chemotherapy along with minimum inhibitory concentration to fluconazoleMulticomponent drug efflux complexes: architecture and mechanism of assembly.Membrane Active Antimicrobial Peptides: Translating Mechanistic Insights to Design.Antibiotic discovery: combatting bacterial resistance in cells and in biofilm communities.An audit of colistin use in neonatal sepsis from a tertiary care centre of a resource-limited country.Biological activity of lactoferrin-functionalized biomimetic hydroxyapatite nanocrystals.Nanoemulsions and nonwoven fabrics carrying AgNPs: antibacterial but may be cytotoxic.Macromolecular Conjugate and Biological Carrier Approaches for the Targeted Delivery of Antibiotics.Computational Insights into the Mechanism of Inhibition of OASS-A by a Small Molecule Inhibitor.
P2860
Q21144908-EC975C98-7F46-4C2F-A5EA-D8E39C30E934Q22255652-CA607615-0A4C-4B9B-ABCD-D566C970C42CQ26863344-AA8F4FBD-842F-437C-A494-4C9DB85E261BQ27658287-38EDE7AB-5565-4A31-88C0-BC3D0B31C3C2Q28553205-8A4B2E52-F547-4F76-A59D-CE82981E2522Q30152790-07AE9A5F-7A6E-4B3B-BEE1-9012F637F20EQ31071398-86926EBB-58C8-49DF-B537-55DBBE383CC2Q33477111-09ABA4C5-F9DF-4AEC-9656-42049671479BQ33715837-6D96D436-D0E0-4FE3-B602-65386A15E261Q33898336-1C1F2221-9964-4AA5-B256-7C8E2F9D89E8Q34108660-6349E28A-993B-4A57-8347-901FAF0D7437Q34510396-58D0460F-D372-476B-A379-092B5D320EADQ34676586-BB62B7D9-69C3-4604-9BCB-E8F772520663Q34680516-A4D23D76-B0FA-4D3B-A0A2-4BD9F3D732A0Q34863109-0BA7E2BE-BE6F-42E7-979A-D9586AB6937CQ35023321-FD2D9702-FD68-4140-B77A-853B51F78A25Q35103860-A61A909F-1DD1-4408-B2C8-16D19306AFDFQ35364351-48527B03-02AA-4BD6-B134-6B6A28014FB4Q35598403-03379816-B9CB-4DA7-9FF4-B94C0A38B10AQ35607968-5E5B8082-11D6-4FC1-9560-A33B78CB99E0Q35746715-4D59A45D-0197-4D77-A5E1-715FBC3A9649Q35864938-2DF212E7-3388-4EBB-A19A-456FED640D78Q36009354-7EDA0808-1B10-48F0-A8A5-B85DEB74CDA6Q36089663-99F4AAE8-B828-40A2-BDAD-7FEFAA5090F3Q36418294-0836206E-6C36-4A72-BAE1-E6A468A904CEQ36544935-3AA4E8B8-C8EA-40BF-9883-056592FB5712Q36611416-A186A55C-853B-4E1C-B23B-A7D80DD31C06Q36719380-2A846F60-6DA8-4447-8C2E-03D53DFE0825Q36719408-AE0155FF-B1C4-4E70-B27C-A5BF8EA2B127Q36732544-39760986-9309-48A0-A101-BA8D61D98359Q36897919-04844636-E0FB-4783-BFF4-9ACCDCF212DCQ37261224-8F7E44AA-9709-4661-B9A8-56A7CD44BB5DQ37590328-1963E7D6-1130-4604-A40A-6F7844B7FF99Q37639825-17494567-04C9-4BF9-BBF0-C65BB258974EQ38392008-0F0CC595-1237-4E86-BDEC-700636969182Q38990099-57158B0E-E7FA-4F4C-8E7F-8D4E46EE375DQ39015999-05071E19-495C-4A2E-96F7-F3D04BBBB767Q39078180-7CAD37DE-9241-4E6B-95E3-00F0E7115345Q39414836-57D8860B-492B-4608-AE0A-7A11BA80AA79Q39535345-BFED5DB2-2220-4165-9604-5947B811CC78
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The need for new antibiotics.
@ast
The need for new antibiotics.
@en
type
label
The need for new antibiotics.
@ast
The need for new antibiotics.
@en
prefLabel
The need for new antibiotics.
@ast
The need for new antibiotics.
@en
P1476
The need for new antibiotics.
@en
P2093
Livermore DM
P356
10.1111/J.1465-0691.2004.1004.X
P478
10 Suppl 4
P577
2004-11-01T00:00:00Z